Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The emerging role of ferroptosis in intestinal disease


Ferroptosis is a newly recognised type of regulated cell death (RCD) characterised by iron-dependent accumulation of lipid peroxidation. It is significantly distinct from other RCDs at the morphological, biochemical, and genetic levels. Recent reports have implicated ferroptosis in multiple diseases, including neurological disorders, kidney injury, liver diseases, and cancer. Ferroptotic cell death has also been associated with dysfunction of the intestinal epithelium, which contributes to several intestinal diseases. Research on ferroptosis may provide a new understanding of intestinal disease pathogenesis that benefits clinical treatment. In this review, we provide an overview of ferroptosis and its underlying mechanisms, then describe its emerging role in intestinal diseases, including intestinal ischaemia/reperfusion (I/R) injury, inflammatory bowel disease (IBD), and colorectal cancer (CRC).


  • Ferroptosis is a unique type of regulated cell death that involves iron accumulation and lipid oxidation.

  • Ferroptosis has been linked to several diseases and cancers, but its role in intestinal disease is uncharacterised.

  • Ferroptosis can be a positive and negative regulator of the disease.

Open questions

  • Does ferroptosis play a role in distinct forms of intestinal diseases?

  • What contributes to ferroptosis in the occurrence and development of intestinal diseases? Are there unknown mechanisms and signalling pathways?

  • Will ferroptosis-related factors be indicators of disease severity?


Ferroptosis is a form of regulated cell death (RCD) that was first proposed by Dixon and colleagues in 20121. It is morphologically, biochemically, and genetically different from other kinds of RCD, such as apoptosis, necroptosis, and autophagy1,2. Iron metabolism and the lipid peroxidation pathway are central mediators of the ferroptotic process3,4 (Fig. 1). Excessive iron regulates ferroptosis by producing lethal reactive oxygen species (ROS) via the Fenton reaction, while reduced glutathione (GSH) depletion and/or glutathione peroxidase 4 (GPX4) inhibition trigger ferroptosis through the accumulation of intracellular lipid ROS and overwhelming lipid peroxidation1,4,5. In addition, ROS attack the polyunsaturated fatty acids (PUFAs) of lipid membranes, producing massive lipid peroxides and leading to membrane damage and cell death4,6. Specific small-molecule compounds, such as erastin and RAS-selective lethal 3 (RSL3) can induce ferroptosis, while ferrostatin-1 (Fer-1), liproxstatin-1 (Lip-1), and iron chelators deferoxamine (DFO) inhibit it7,8. Accumulating evidence suggests that ferroptosis participates in multiple diseases, including neurological disorders, ischaemia/reperfusion (I/R) injury, kidney failure, cardiac disease, and cancer1,4,9,10,11. Recent studies have also implicated ferroptosis in intestinal diseases, including intestinal I/R injury, inflammatory bowel disease (IBD), and colorectal cancer (CRC)12,13,14,15,16 (Fig. 2 and Table 1). Ferroptosis has been reported in ulcerative colitis (UC) in both humans and mice; moreover, blocking the ferroptotic process alleviated dextran sulphate sodium (DSS)-induced colitis12,13. Furthermore, ferroptosis can limit the migration, invasion, and proliferation of CRC. Indeed, RSL3 drives ferroptotic cell death by promoting cellular ROS accumulation and increasing iron load17. Another report indicated that in CRC, resibufogenin inhibited cell growth and tumorigenesis by inducing ferroptosis through GPX4 inactivation18. Taken together, ferroptosis appears to play a key role in the pathophysiological processes and may provide new ideas and means for the treatment of intestinal diseases. This review presents a comprehensive description of ferroptosis and its emerging role in multiple intestinal diseases.

Fig. 1: Mechanisms of ferroptosis.

Ferroptosis is characterised by iron accumulation, excessive ROS production and overwhelming lipid peroxidation. Three main metabolic pathways, amino-acid/GSH, lipid, and iron pathways, participate in the initiation and execution of ferroptosis. Moreover, there are additional signalling pathways and regulators controlling ferroptosis sensitivity. This illustration shows the process of ferroptosis, summarising the key molecules and targets that regulate iron and lipid peroxidation. ACSL4 acyl-CoA synthetase long-chain family member 4, BSO buthionine sulphoximine, CISD1 CDGSH iron sulphur domain 1, DMT1 divalent metal transporter 1, FSP1 ferroptosis suppressor protein 1, FPN1 ferroportin 1, GPX4 glutathione peroxidase 4, GSH glutathione, GSSG oxidized glutathione, GSS glutathione synthetase, GCL glutamate-cysteine ligase, HO-1 haem oxygenase 1, HSPB1 heat shock protein beta-1, IREB2 iron response element-binding protein 2, LOX lipoxygenase, LPCAT3 lysophosphatidylcholine acyltransferase 3, NCOA4 nuclear receptor coactivator 4, NRF2 nuclear factor E2-related factor 2, PUFA polyunsaturated fatty acid, PE phosphatidylethanolamine, ROS reactive oxygen species, RSL3 Ras-selective lethal 3, STEAP3 six-transmembrane epithelial antigen of prostate 3 metalloreductase, SLC7A11 solute carrier family 7 member 11, SAS sulphasalazine, SRF sorafenib, TF transferrin, TFR1 transferrin receptor 1, VDAC2/3 voltage dependent-anion channel 2/3.

Fig. 2: Dual regulatory roles for ferroptosis in intestinal diseases.

Ferroptosis can be a positive and negative regulator of intestinal diseases according to cell type and disease context. The induction of ferroptosis by multiple compounds can inhibit cancer growth; however, inhibiting ferroptosis has an anti-inflammatory effect and can attenuate intestinal injury in IBD and I/R injury. This schematic diagram shows ferroptosis regulators and pathways. ACADSB acyl-Coenzyme A dehydrogenase short/branched chain, ACSL4 acyl-CoA synthetase long-chain family member 4, ANO6 anoctamin 6, CRC colorectal cancer, CXCL1 chemokine (C-X-C motif) ligand 1, DFO deferoxamine, DPP4 dipeptidyl-peptidase-4, ER endoplasmic reticulum, Fer-1 ferrostatin-1, FTL ferritin light chain, FTH1 ferritin heavy chain 1, FeOOH NS iron oxide-hydroxide nanospindle, GPX4 glutathione peroxidase 4, GSH glutathione, HO-1 haem oxygenase 1, IMCA 2-Imino-6-methoxy-2H-chromene-3-carbothioamide, I/R ischaemia/reperfusion, IBD inflammatory bowel disease, IL-6 interleukin 6, KD knockdown, Lip-1 liproxstatin-1, NOX1 NADPH oxidase 1, NRF2 nuclear factor E2-related factor 2, PUFA polyunsaturated fatty acid, PE phosphatidylethanolamine, ROS reactive oxygen species, RSL3 Ras-selective lethal small molecule 3, SLC7A11 solute carrier family 7 member 11, TFR1 transferrin receptor 1.

Table 1 Mechanisms of ferroptosis in intestinal diseases.

Ferroptosis: an iron-dependent type of regulated cell death with clinical significance

Definition and measurement

Since 2003, Stockwell and colleagues have successively identified novel compounds, including erastin and RSL3, that activate new, nonapoptotic cell death in particular cancer cells19,20. Inhibitors specific to known RCDs did not inhibit this chemically induced cell death; however, antioxidants and iron chelators could block and reverse the process21. The definition of ferroptosis was proposed in 2012: nonapoptotic, iron-dependent cell death characterised by the accumulation of lipid peroxidation products and the depletion of membrane PUFAs1. Ferroptosis was added to the RCD family by the Nomenclature Committee on Cell Death (NCCD) in 201822. Morphologically, ferroptosis manifests as small mitochondria with concentrated membrane density, decreased or vanishing mitochondrial cristae, and outer mitochondrial membrane rupture4,23. The biochemical properties of ferroptosis are iron accumulation, lethal ROS production, and overwhelming lipid peroxidation4,10. Multiple molecules, including GPX4, p53, solute carrier family 7 member 11 (SLC7A11), acyl-CoA synthetase long-chain family member 4 (ACSL4), NADPH oxidase (NOX), and nuclear factor E2-related factor 2 (NRF2) positively or negatively regulate ferroptosis1,24,25,26.

To assess ferroptosis, the Cell Counting Kit-8 and propidium iodide staining can be used to measure cell viability and death9,27. Measuring lipid peroxidation is important for evaluating the presence of ferroptosis in specific contexts. Oxidative lipidomics is the gold standard for identifying specific oxidized lipids28,29. Probes such as C11-BODIPY and Liperfluo provide indirect but efficient means to detect lipid ROS2,30. Moreover, malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) are common by-products of lipid peroxidation during oxidative stress that allow the measurement of lipid peroxidation31. Another method for evaluating ferroptosis is to test cellular iron levels using an iron assay kit or the fluorescent probe Phen Green SK (PGSK)20,32. We can also detect changes in ferroptosis-related gene expression, such as prostaglandin-endoperoxide synthase (PTGS), ACSL4, GPX4, and ferritin heavy chain 1 (FTH1)33. In addition, transmission electron microscopy can be used to identify specific morphological features of cells to support ferroptosis occurrence34.

Mechanisms and mediators of ferroptosis

GSH/GPX4-lipid peroxidation pathway

Ferroptosis is triggered by excessive lipid peroxidation arising from iron-dependent ROS accumulation. As it can occur when GSH-dependent lipid peroxide repair systems are compromised, maintaining ROS and lipid peroxides at physiological concentrations is a critical factor in minimizing susceptibility2,35. Lipophilic antioxidants (e.g. Fer-1, Lip-1) have been defined as specific ferroptosis suppressors that inhibit ROS accumulation caused during lipid oxidation. GSH is a thiol-containing tripeptide that plays an essential role in intracellular antioxidant defences. Its depletion causes increased oxidative stress, macromolecular damage, and subsequent cell death36. GPX4 is a member of the glutathione peroxidase family capable of reducing cytotoxic lipid hydroperoxides (L-OOH) to non-toxic lipid alcohols (L-OH) or catalysing free hydrogen peroxide into water to prevent the formation and accumulation of lethal lipid ROS at the expense of GSH37,38.

Accumulating evidence has implicated GPX4 as a master regulator of ferroptosis; its inhibition by pharmacological or genetic methods can trigger ferroptotic cell death through the accumulation of lipid peroxides5,39,40. Indeed, RSL3 has been shown to induce ferroptosis by directly inhibiting GPX4 activity through covalent binding with the selenocysteine active site of GPX45,41. GPX4 can also be inactivated by indirect methods, such as cellular GSH depletion. The biosynthesis of GSH requires the participation of glutamate, cysteine, and glycine in a two-step reaction catalysed by glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS)42,43. Thus, GSH depletion can result either from direct inhibition of GSH synthesis (e.g. by the known GCL inhibitor buthionine sulphoximine (BSO)6) or from cysteine/glutamate unavailability. Cysteine, the rate-limiting substrate for GSH biosynthesis, is produced from dipeptide cystine imported by the cell surface cystine/glutamate antiporter system Xc, or from methionine via the transsulphuration pathway44,45. Inhibiting system Xc can reduce GSH levels and GPX4 activity, contributing to ferroptotic cell death. Erastin and other molecules (e.g. sulphasalazine, sorafenib) are inhibitors of system Xc and thus induce ferroptosis1,3,4. Studies have shown that regulating the expression of SLC7A11, the functional subunit of system Xc, affects system Xc activity and ferroptosis sensitivity in cancer cells24,26,44. Furthermore, cysteinyl-tRNA synthetase (CARS) has been found to participate in the transsulphuration pathway; its knockdown causes upregulation of this pathway and erastin-induced ferroptosis resistance2.

As described below, disruption of lipid repair systems involving GSH and GPX4 can facilitate the accumulation of (lipid) ROS; however, cysteine/GSH depletion and/or GPX4 suppression alone is not sufficient to cause ferroptosis. ROS react with PUFAs of lipid membranes to cause lipid peroxidation, which is central to the final execution of ferroptosis. Free PUFAs are substrates for the synthetic-lipid signal-transduction medium, but they must be esterified and incorporated into membrane phospholipids (PLs) with the help of the enzymes ACSL4 and lysophosphatidylcholine acyltransferase 3 (LPCAT3). Then lipoxygenases (LOXs) catalyse PUFA‐containing PLs to produce pro‐ferroptotic lipid peroxidation23. Researchers have identified ACSL4 as both a biomarker for, and a critical contributor to, ferroptosis25,46. ACSL4 expression is positively correlated with ferroptosis sensitivity; in addition, lipid oxidation upon GPX4 inhibition requires the involvement of ACSL425,46. One group has reported that LPCAT3 deletion protected fibroblasts against ferroptosis, suggesting that LPCAT3 is also an important player in ferroptosis25. However, this protective effect was mild compared with the protection provided by ACSL4 deletion, suggesting that ACSL4 plays a more extensive role in ferroptosis; moreover, the functional effect of LPCAT3 possibly depends on cellular subtypes25,47. Of the different oxidised PL species, PUFA-containing phosphatidylethanolamines (PEs), especially arachidonic acid (AA)- and adrenic acid (AdA)-containing PEs, are the most susceptible to peroxidation in ferroptosis48. Finally, overwhelming lipid peroxidation likely alters lipid bilayer properties, producing cytotoxic reactive fragments, and leading to irreversible cell death49.

Iron metabolism and ferroptosis

Iron is a redox-active element that promotes ROS generation through the Fenton reaction, which leads to non-enzymatic lipid peroxidation3,50. Iron also serves as a cofactor for iron-containing enzymes, including LOXs, suggesting a necessary role in enzymatic lipid reactions50. Thus, as a significant factor for the production of (lipid) ROS via enzymatic or non-enzymatic ways, iron appears to be an indispensable component in ferroptosis1,2. The chelation of intracellular iron by DFO and ciclopirox olamine is sufficient to inhibit erastin-induced cell death, reinforcing the importance of iron in ferroptosis4. Normally, extracellular iron forms a complex with circulating transferrin (TF), binds to the specific membrane transferrin receptor protein-1 (TFR1), and is delivered into cells. Excess cellular iron is stored as ferritin, the main intracellular iron storage protein that consists of a ferritin light chain (FTL) polymer and FTH1, or exported by iron exporter ferroportin (FPN)51,52. Maintaining cellular iron homoeostasis can prevent oxidative damage, and cell toxicity and death. Either reduced iron storage or increased iron uptake can cause iron overload and trigger ferroptosis4. Recent studies have revealed an association between genes involved in iron metabolism and ferroptosis. Erastin-induced ferroptosis can be prevented by silencing TFRC, the gene that encodes TFR1, whereas overexpression of haem oxygenase 1 (HO-1) alters iron homoeostasis and aggravates it6,53. Autophagic degradation of ferritin, known as ferritinophagy, modulated by the nuclear receptor coactivator 4 (NCOA4), controls cellular liable iron levels and ROS accumulation, thus regulating ferroptotic cell death in some cell lines54,55. The pentaspan membrane protein prominin-2 can drive ferroptosis resistance by promoting the formation of ferritin-containing multivesicular bodies and exosomes, thus exporting iron from the cell56. Furthermore, iron response element-binding protein 2 (IREB2) encodes the master regulator of iron metabolism, which results in the expression of TRFC, FTH1, and FTL. Inhibiting IREB2 expression contributes to decreased sensitivity to erastin-induced ferroptosis1. Other targets, such as heat shock protein beta-1 (HSPB1) and CDGSH iron sulphur domain 1 (CISD1), can also regulate ferroptotic cell death by mediating iron uptake and lipid peroxidation57,58. Collectively, these findings indicate the iron dependence of ferroptosis.

Other ferroptosis regulatory pathways

The canonical tumour suppressor p53 probably plays dual roles in mediating ferroptosis in multiple cancers (Fig. 3). It can directly adjust the metabolic versatility of cells by modulating metabolic targets, favouring mitochondrial respiration and resulting in ROS-mediated cell death59. Researchers have found that p53 represses SLC7A11 protein expression, resulting in decreased cystine import, decreased GSH production, and enhanced ROS-mediated ferroptosis in some cancer cell lines24,59. The acetylation-defective mutant p533KR, which lacks the ability to trigger apoptosis, cell-cycle arrest, and senescence, can suppress tumourigenesis by inhibiting SLC7A11 and inducing ferroptosis24. On the contrary, other studies have reported an inhibitory effect of p53 on ferroptosis in different contexts. Wild-type p53 stabilisation suppresses ferroptosis in specific cancer cell lines in response to cystine deprivation and system Xc inhibition because of the activation of p53–p21 transcriptional axis60. Besides, p53 negatively regulates ferroptosis in CRC cells by inhibiting dipeptidyl-peptidase-4, described in more detail in section ‘Ferroptosis and colorectal cancer’ below61. In addition to p53-mediated ferroptosis, the intracellular metabolic process glutaminolysis is required for the initiation of cystine deprivation-induced ferroptosis9. The FSP1–CoQ10–NAD(P)H pathway exists as an independent parallel system that cooperates with GSH/GPX4 to mitigate lipid peroxidation and ferroptosis62. Targeting the NRF2-related pathway is also a vital strategy to mediate lipid peroxidation and ferroptosis63.

Fig. 3: p53-mediated ferroptosis.

p53 plays a dual role in the regulation of ferroptosis through transcriptional or posttranslational mechanisms in different contexts. On one hand, p53 induces ferroptosis through inhibition of SLC7A11 or upregulation of GSL2 and SAT1–ALOX pathway. On the other hand, p53 also inhibits ferroptosis through inhibition of DPP4 activity or by the transcriptional activation of CDKN1A/p21. ALOX arachidonate lipoxygenase, CDKN1A cyclin-dependent kinase inhibitor 1 A, DPP4 dipeptidyl-peptidase-4, GLS2 glutaminase 2, GSH glutathione, NOX1 NADPH oxidase 1, ROS reactive oxygen species, SAT1 spermidine/spermine N1-acetyltransferase 1, SLC7A11 solute carrier family 7 member 11.

The significance of ferroptosis research in disease

In parallel with more basic research, it has been found that inducing or blocking ferroptosis can affect the onset and development of multiple pathogenic conditions, providing a potential target for therapeutics, especially for diseases tolerant/resistant to conventional drugs. Taking drug-resistant cancer as an example, ineffective induction of cancer cell death is an important problem with many chemotherapy and bio-targeted drugs, closely linked to drug resistance64. Persister cells are clones that survive initial cancer treatment and induce drug-resistant states across diverse cancer contexts64,65. Interestingly, induction of ferroptosis can kill these drug-tolerant persister cells and decrease the emergence of acquired drug resistance66,67. In addition, the epithelial-to-mesenchymal transition (EMT) is one of the mechanisms leading to apoptotic failure and drug resistance in epithelial-derived carcinoma cells68. Evidence has indicated that tumour cells in a high-mesenchymal state are characterised by enhanced activity of enzymes related to the promotion of PUFA synthesis, making these cells dependent on the lipid peroxidase pathway involving GPX4. Thus, cancer cells in a mesenchymal state can undergo ferroptosis through pharmacological perturbations to overcome cancer therapy resistance68. Targeting ferroptosis is a new perspective for the treatment of kidney injury, non-cancer liver diseases, and intestinal diseases, suggesting the significant potential of ferroptosis research10,69.

Ferroptosis in intestinal disease

Ferroptosis and intestinal ischaemia/reperfusion (I/R) injury

Intestinal I/R injury is a common clinical condition with high morbidity and mortality, resulting from sudden reduction of intestinal blood flow and reoxygenation after the restoration of blood supply70. It occurs in many clinical conditions, including trauma, haemorrhagic shock, acute mesenteric ischaemia, small intestinal volvulus, and intestinal transplantation71,72. Intestinal mucosal barrier dysfunction, as a consequence of epithelial cell death, can allow the translocation of bacteria and associated toxins into the bloodstream, leading to inflammation, systemic sepsis, and organ dysfunction73,74. Intestinal I/R injury is associated with multiple types of RCD, including apoptosis, necroptosis, and autophagy, but with the discovery of ferroptosis, new potential mechanisms of RCD have attracted attention75,76,77. Indeed, ferroptosis has been identified in I/R injury in other organs both in vivo and in vitro; moreover, ferroptosis inhibitors can alleviate these injuries. Studies have shown that treatment with DFO reduced myocardial infarct size and lactate dehydrogenase levels in an ex vivo heart model of I/R stress9, while Lip-1 prevented acute renal failure from renal I/R injury39. ROS generation and lipid peroxidation are associated with intestinal I/R injury and are primary contributors to the initiation and execution of ferroptosis78. Decreased GSH levels and superoxide dismutase activity, as well as increased MDA levels, were observed in rat intestinal tissues after intestinal I/R79,80. Furthermore, DFO administration was beneficial in the prevention of intestinal I/R-induced lipid peroxidation and GPX activity reduction was reversed by DFO treatment81. Taken together, lipid peroxidation and iron participate in I/R-induced intestinal injury, but their contribution to ferroptosis is still enigmatic.

A recent study has reported that ferroptosis plays a critical role in intestinal I/R injury and may be a lethal process triggered by reperfusion14. In this study, the expression levels of pro-ferroptotic factors such as ACSL4 and iron increased, while those of anti-ferroptotic factors (GPX4, FTH1, GSH) decreased in ischaemic murine intestinal tissues; moreover, treatment with Lip-1 ameliorated intestinal injury both in vivo and in vitro14. Moreover, an ischaemia model that incorporated different reperfusion durations to examine features of ferroptosis in situ suggested that this form of cell death occurred in the early phase of reperfusion and was distinct from apoptosis, which appeared at a later phase14. Inhibition of ischaemia-induced ACSL4 (a key regulator and indicator of ferroptosis) expression via pharmacological and genetic manipulations protected against lipid peroxidation and ferroptosis, as well as alleviated cell damage and intestinal barrier dysfunction induced by intestinal I/R14,25. Li and colleagues have further shown that Sp1, a transcription factor that binds to GC-box motifs in target-gene promoters, mediated ACSL4 expression14. In addition to intestinal damage, intestinal I/R can cause acute injury to remote organs, including the lungs and liver. Indeed, ferroptosis was reported to exacerbate intestinal I/R-induced acute lung injury, whereas blocking this process mitigated lung injury after intestinal I/R in mouse models14,82. In summary, ferroptosis is related to I/R-induced intestinal injury, but more studies are needed to discover its underlying mechanisms and regulation.

Ferroptosis and inflammatory bowel disease

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic disease characterised by constant progression and relapse. Although not fully elucidated, the aetiology of IBD is commonly thought to implicate reciprocal interactions between host genetics, environmental factors, the gut microbiome, and immune responses83. A better understanding of IBD pathogenesis will be beneficial for improving its treatment; recent studies have underlined the importance of cell death in intestinal epithelial homoeostasis. Excessive cell death is closely correlated with chronic inflammation in IBD patients84, but what is the relationship between ferroptosis and IBD? It has been reported that iron supplementation changes gut microbial homoeostasis and exacerbates intestinal inflammation similarly to CD in a murine model85. Another study using a rat model of DSS-induced colitis also indicated that excess iron aggravated intestinal inflammation86. Recently, a Japanese team showed that high dietary iron intake increased the risk of UC87. Mucosal ROS production is increased in UC in proportion to the disease activity, and iron chelators are known to reduce ROS production and ameliorate colonic symptoms in IBD88,89. Taken together, these findings suggest a possible relationship between IBD and ferroptosis in which excess iron in the intestine produces ROS via the Fenton reaction, which triggers oxidative stress. Lipid peroxidation procedurally appears and ferroptotic cell death is induced. Thereby, the intestinal epithelial cells are destroyed, and damage to the intestinal mucosal barrier results in IBD90.

Ferroptosis has been implicated in both clinical UC patients and in murine experimental colitis, with significant downregulation and upregulation of ferroptosis-associated genes12,13. Administration of ferroptosis inhibitors, including Fer-1, Lip-1, and DFO, reduced disease activity scores and ameliorated colon length shortening in DSS-induced murine colitis, suggesting the beneficial effect of inhibiting ferroptosis12,13,91. In keeping with ferroptosis mechanisms, GPX4 also plays a vital role in negatively regulating ferroptotic cell death in IBD. Curculigoside (CUR) is a botanical ingredient with anti-oxidant and anti-inflammatory properties that protects against ferroptosis in UC through the promotion of GPX491. CUR increased selenium sensitivity and enhance GPX4 expression levels in the IEC-6 rat intestinal epithelial cell line, while Gpx4 silencing inhibited the protective effects of CUR on cell death and oxidative stress indicators in ferroptotic IEC-6 cells91. Moreover, another group emphasised the importance of GPX4 in gut homoeostasis by showing impaired GPX4 activity and features of lipid peroxidation in the small intestinal epithelial cells (IECs) of CD patients92. PUFAs, especially AA, induced the production of interleukin 6 (IL-6) and chemokine (C-X-C motif) ligand 1 (CXCL1) in IECs treated with Gpx4 siRNA in response to iron availability, lipid peroxidation, and ACSL4, similar to ferroptosis mechanisms92. Interestingly, a PUFA-enriched Western diet triggered small intestinal inflammation in mice that lacked one Gpx4 allele in IECs, with histological characteristics resembling CD92. The link between PUFA uptake, GPX4 activity, and intestinal inflammation further provides evidence for the pathogenesis of CD. However, although the process observed in the study was similar to ferroptosis, no definite cell death was observed in the murine intestinal inflammation model; the scholars speculate that in this case, one Gpx4 allele might be sufficient to protect against ferroptotic cell death92.

NRF2 is a critical mediator of the cellular antioxidant response that controls redox homoeostasis-related gene expression; perturbations of the NRF2-lipid peroxidation–ferroptosis axis have been found in cancers63. HO-1, a cytoprotective enzyme related to cellular stress, also participates in ferroptosis and has anti-inflammatory effects93. Chen et al. found that Fer-1 alleviated DSS-induced colitis via NRF2/HO-1 signalling, indicating that the NRF2 pathway may be an important factor regulating ferroptosis in UC12. ER stress can induce the cell-death signalling pathway in the form of apoptosis and autophagy94,95, but interestingly, ER stress also is implicated in the development of ferroptosis in diseases, including IBD13,96. It has been found that ferroptosis contributed to UC via ER stress-mediated IEC cell death; moreover, phosphorylation of NF-κBp65 inhibited ER stress-mediated IEC ferroptosis to relieve the disease as an upstream regulator13. Together, these data show that ferroptosis has a key role in IBD, and that targeting it may be a promising method for understanding the development of IBD and to provide new treatments.

Ferroptosis and colorectal cancer

Colorectal cancer (CRC) is a common malignant tumour with high morbidity and mortality and is one of the most pressing global health issues. According to the GLOBOCAN 2018 estimates of incidence and mortality worldwide report, CRC is the third-most diagnosed cancer and the second-most cause of cancer-related deaths globally97. Current treatments for CRC include surgery, radiotherapy, chemotherapy, immune therapy, and bio-targeted therapy98; however, despite recent progress in therapeutics, some patients exhibit resistance or intolerance to them via apoptosis evasion and anti-apoptotic enhancement99,100. Thus ferroptosis, as a form of RCD independent from apoptosis, may provide a promising strategy for cancer therapy. Since its discovery in 2012, the manipulation of ferroptosis by specific molecules has enabled inhibition of the growth and spread of multiple cancer types, including CRC1,23. RSL3-induced ferroptosis in a dose-and time-dependent manner in three CRC cell lines; this treatment increased ROS and cellular labile iron pool (LIP) levels17. Evidence has showed that the classic chemotherapy drug cisplatin induces ferroptosis; moreover, the combination of cisplatin and erastin was synergistic, indicating that ferroptosis adds an alternative cell-death pathway triggered by classical therapeutic drugs and anti-tumour mechanisms in CRC100. In addition, targeting ferroptosis can overcome conventional CRC drug resistance from a new perspective. Chen et al. reported that the bioactive compound β-elemene (extracted from the Chinese herb Curcumae Rhizoma) is a ferroptosis inducer; they combined treatment with β-elemene and anti-EGFR (epidermal growth factor receptor) antibody cetuximab to produce anti-tumour effects by triggering ferroptosis in CRC patients with RAS mutations that do not respond to cetuximab99,101. Another study showed that vitamin C, an antioxidant that can paradoxically initiate oxidative stress at pharmacological doses, targeted cetuximab-persister cells and restricted the emergence of acquired resistance to EGFR blockade in CRC through the induction of ferroptosis67. Altogether, the role of ferroptosis in CRC in inhibiting tumour growth and overcoming resistance to current anticancer drugs is a promising avenue for research.

As described above, GPX4 plays a central role in regulating ferroptosis. Recently, several molecules have been implicated in ferroptosis in CRC through their mediation of GPX4. RSL3 inhibits GPX4 activity by directly binding with GPX4, and overexpression of GPX4 rescued CRC cell death induced by RSL3, suggesting a similar role of GPX4 in RSL3-induced ferroptosis in CRC as in other diseases17. Shen et al. found that resibufogenin isolated from Asiatic toad dried skin secretions is a potential anticancer agent in the treatment of CRC because it induced ferroptosis in a GPX4 inactivation-dependent manner18. In addition to direct GPX4 inhibition, inhibiting SLC7A11, the functional subunit of system Xc, also induces ferroptotic cell death in CRC. It was reported that the benzopyran derivative 2-imino-6-methoxy-2H-chromene-3-carbothioamide (IMCA) has a wide spectrum of biological activities, including those relevant to cancer therapy102. Zhang et al. first discovered the anti-CRC effect of IMCA through ferroptosis induction by downregulating SLC7A11103. Interestingly, IMCA affected the downstream components of the AMPK/mTOR/p70S6k pathway, which have been linked to SLC7A11 activity and ferroptosis103. The role of SLC7A11 and ferroptosis has also been elucidated in colorectal cancer stem cells (CSCs), which can provide resistance to chemotherapy and form secondary tumours in the progression of CRC104. Colorectal CSCs are more sensitive to ferroptosis than parental CRC cells; the knockout of SLC7A11 with CRISPR-Cas9 technology facilitated ferroptotic cell death, suggesting that targeting SLC7A11 may specifically suppress the progression of colorectal CSCs and reduce CRC drug resistance105. Another key regulator of ferroptosis in many related diseases is ACSL425. A recent study has determined its crucial regulatory role in the induction of ferroptosis by bromelain (a plant extract derived from pineapple) in KRAS-mutant CRC through signalling pathway and miRNA profiling106.

The TP53 gene is known as a tumour suppressor and ferroptosis regulator in multiple cancers. It inhibited ferroptotic CRC cell death by blocking dipeptidyl-peptidase-4 (DPP4) activity, while the loss of p53 increased the anticancer activity of erastin in tumour-bearing mice, very different from the positive regulation of ferroptosis by p53 in other cancers (Fig. 3)61. Specifically, the loss of p53 restrains DPP4 nuclear localisation and facilitates the formation of the DPP4–NOX1 complex that promotes lipid peroxidation, resulting in ferroptosis in the HCT116 human CRC cell line59,61. While p53 can limit ferroptosis by forming a DPP4–p53 complex in the nucleus, disassembly of this complex restores the erastin-induced ferroptosis sensitivity of CRC59,61. Moreover, the fact that TP53 can stimulate SLC7A11 expression in CRC protects CRC cells from ferroptosis61. Therefore, regulation of TP53 may be highly desirable as part of CRC therapy. In a human miRNome analysis of miRNA–mRNA interactions and multiple pathways involved in CRC pathogenesis, three downregulated miRNAs, let-7c, let-7e, and miR-150-5p, were found to modulate TP53 in CRC and thus could regulate ferroptosis107.

There also are connections between ferroptosis and other types of RCDs in CRC. Hong et al. reported molecular crosstalk between ferroptosis and apoptosis when CRC cells were treated with the ferroptotic agents erastin or artesunate (ART) in combination with the apoptotic agent tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)108. The combination of erastin/ART and TRAIL significantly promoted TRAIL-induced apoptosis due to ER stress-induced p53-independent PUMA (p53 upregulated modulator of apoptosis) expression108. The group further found that ER stress response-mediated expression of the TRAIL receptor death receptor 5 (DR5) also played a vital role in this combinatorial synergy in a variety of CRC cell lines109. These studies are preliminary explorations of the mechanisms that may be shared between ferroptosis and apoptosis, but further research is needed to understand the relationship between these RCDs. Autophagy promotes ferroptotic cell death through the degradation of ferritin (ferritinophagy) in fibroblasts and certain cancer cells, modulated by selective cargo receptor NCOA454,55; its inhibition suppresses ferritin degradation and inhibits ferroptosis in these cells54,55. However, this is not the case for CRC cells; Hasan et al. indicated that ferritinophagy was not required for CRC cell growth110. Interestingly, knocking out NCOA4 did not alter ferroptosis in CRC110. Differences in cell lines may partially explain these conflicting findings, but another possibility is that CRC cells have an alternative mechanism that compensates for the loss of NCOA4 function in response to ferroptosis induction. Future studies should investigate the compensatory and alternative pathways in CRC that enhance cell survival.

Taken together, ferroptosis plays a significant role in CRC, and its regulation may provide new insights into cancer therapy. In addition to the regulators already mentioned, researchers also have identified novel compounds, for example, iron oxide-hydroxide nanospindles, with the potential to promote ferroptosis to inhibit colon cancer111. Researchers also have identified new targets which can regulate ferroptosis in CRC, including the short/branched chain acyl-coenzyme A dehydrogenase and anoctamin 6112,113. We believe that fully understanding ferroptosis and its underlying mechanisms in CRC, as well as the connections between ferroptosis and other RCDs, can give us hope to improve the treatment and prognosis of this cancer.

Conclusions and perspectives

Ferroptosis is a newly identified type of RCD that is mediated by the iron-dependent accumulation of lipid ROS and has been implicated in the development of a wide variety of disorders, especially intestinal diseases. Inhibiting ferroptosis can attenuate intestinal injury in non-infectious inflammatory conditions such as intestinal I/R injury and IBD, while inducing ferroptosis with pharmacological activators can inhibit the migration, invasion, and proliferation of colorectal neoplasms, suggesting a dual role for ferroptosis in different intestinal diseases. As shown in Fig. 2, the common ferroptotic mechanisms in intestinal diseases include GPX4 inhibition, system Xc suppression, lipid peroxide accretion, and iron overload, which are consistent with other diseases. Key regulators such as GPX4, SLC7A11, ACSL4, and p53 are also important for mediating ferroptosis-associated intestinal diseases. In addition to known ferroptotic inducers (erastin, RSL3) and inhibitors (Fer-1, Lip-1, DFO), researchers have found more drugs and targets related to ferroptosis in intestinal diseases (Table 1). However, whether there are specific regulators or signalling pathways in these diseases remains unclear. Interestingly, some regulators seem to play different roles in intestinal diseases compared with diseases in other organs, for example, p53 and NCOA4 in CRC. As a result, further research is needed to identify disease-specific ferroptotic mechanisms to develop disease context-dependent therapeutic regimens. Furthermore, studies have found correlations between ferroptosis and other forms of cell death in intestinal diseases. These RCDs may share common pathways and key regulators, which can provide new directions for combining different therapeutic interventions.

Although much progress has been made, research on intestinal ferroptosis is still at an early stage, and its specific role remains to be investigated across the spectrum of intestinal disease, including many not presented in this review. Although we have summarized multiple methods for assaying ferroptosis from multiple aspects, no unanimously agreed-upon criteria directly define its occurrence. It is imperative to identify markers and other approaches to assess ferroptosis in vivo. In this way, ferroptosis biomarkers could be promising to indicate intestinal disease severity. We caution that the relationship between ferroptotic cell death and iron/lipid peroxides remains controversial, so more evidence is required to support the links between ferroptosis and iron, oxidative stress, and lipid peroxidation in disease development and progression. In addition, the signalling pathways and main transcriptional regulators of ferroptosis need to be studied so that we can benefit more from its modulation to protect the intestine against injury and carcinogenesis. Therefore, ferroptosis should be further investigated within the field of intestinal disease as a novel therapeutic target.


  1. 1.

    Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273–285 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Dixon, S. J. & Stockwell, B. R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10, 9–17 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  4. 4.

    Xie, Y. et al. Ferroptosis: process and function. Cell Death Differ. 23, 369–379 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Cao, J. Y. & Dixon, S. J. Mechanisms of ferroptosis. Cell Mol. Life Sci. 73, 2195–2209 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Imai, H., Matsuoka, M., Kumagai, T., Sakamoto, T. & Koumura, T. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis. Curr. Top. Microbiol. Immunol. 403, 143–170 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Angeli, J. P. F., Shah, R., Pratt, D. A. & Conrad, M. Ferroptosis inhibition: mechanisms and opportunities. Trends Pharm. Sci. 38, 489–498 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  9. 9.

    Gao, M., Monian, P., Quadri, N., Ramasamy, R. & Jiang, X. Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59, 298–308 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Hu, Z. et al. Emerging role of ferroptosis in acute kidney injury. Oxid. Med Cell Longev. 2019, 8010614 (2019).

    PubMed  PubMed Central  Google Scholar 

  11. 11.

    Del, Re. D. P., Amgalan, D., Linkermann, A., Liu, Q. & Kitsis, R. N. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol. Rev. 99, 1765–1817 (2019).

    Article  CAS  Google Scholar 

  12. 12.

    Chen, Y., Zhang, P., Chen, W. & Chen, G. Ferroptosis mediated DSS-induced ulcerative colitis associated with Nrf2/HO-1 signaling pathway. Immunol. Lett. 225, 9–15 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    Xu, M. et al. Ferroptosis involves in intestinal epithelial cell death in ulcerative colitis. Cell Death Dis. 11, 86 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Li, Y. et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 26, 2284–2299 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Song, Y., Yang, H., Lin, R., Jiang, K. & Wang, B. M. The role of ferroptosis in digestive system cancer. Oncol. Lett. 18, 2159–2164 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Nie, J., Lin, B., Zhou, M., Wu, L. & Zheng, T. Role of ferroptosis in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 144, 2329–2337 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    Sui, X. et al. RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. Front Pharm. 9, 1371 (2018).

    CAS  Article  Google Scholar 

  18. 18.

    Shen, L. D. et al. Resibufogenin inhibited colorectal cancer cell growth and tumorigenesis through triggering ferroptosis and ROS production mediated by GPX4 inactivation. Anat. Rec. (Hoboken) 304, 313–322 (2021).

    CAS  Article  Google Scholar 

  19. 19.

    Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285–296 (2003).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Yang, W. S. & Stockwell, B. R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 15, 234–245 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Capelletti, M. M., Manceau, H., Puy, H. & Peoc’h, K. Ferroptosis in liver diseases: an overview. Int. J. Mol. Sci. 21, 4908 (2020).

    CAS  PubMed Central  Article  Google Scholar 

  22. 22.

    Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018).

    PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Li, J. et al. Ferroptosis: past, present and future. Cell Death Dis. 11, 88 (2020).

    PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57–62 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91–98 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  26. 26.

    Sun, X. et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63, 173–184 (2016).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  27. 27.

    Yu, Y. et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol. Cell Oncol. 2, e1054549 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  28. 28.

    Tyurin, V. A. et al. Oxidative lipidomics of programmed cell death. Methods Enzymol. 442, 375–393 (2008).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  29. 29.

    Wiernicki, B. et al. Excessive phospholipid peroxidation distinguishes ferroptosis from other cell death modes including pyroptosis. Cell Death Dis. 11, 922 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Drummen, G. P., van Liebergen, L. C., Op den Kamp, J. A. & Post, J. A. C11-BODIPY(581/591), an oxidation-sensitive fluorescent lipid peroxidation probe: (micro)spectroscopic characterization and validation of methodology. Free Radic. Biol. Med. 33, 473–490 (2002).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  31. 31.

    Ayala, A., Muñoz, M. F. & Argüelles, S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell Longev. 2014, 360438 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  32. 32.

    Xian, Z. Y. et al. CircABCB10 silencing inhibits the cell ferroptosis and apoptosis by regulating the miR-326/CCL5 axis in rectal cancer. Neoplasma 67, 1063–1073 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  33. 33.

    Mou, Y. et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J. Hematol. Oncol. 12, 34 (2019).

    PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Doll, S. & Conrad, M. Iron and ferroptosis: a still ill-defined liaison. IUBMB Life 69, 423–434 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  35. 35.

    Kajarabille, N. & Latunde-Dada, G. O. Programmed cell-death by ferroptosis: antioxidants as mitigators. Int. J. Mol. Sci. 20, 4968 (2019).

    CAS  PubMed Central  Article  Google Scholar 

  36. 36.

    Martin, H. L. & Teismann, P. Glutathione-a review on its role and significance in Parkinson’s disease. FASEB J. 23, 3263–3272 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Ursini, F., Maiorino, M., Valente, M., Ferri, L. & Gregolin, C. Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. Biochim. Biophys. Acta 710, 197–211 (1982).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    Brigelius-Flohé, R. & Maiorino, M. Glutathione peroxidases. Biochim. Biophys. Acta 1830, 3289–3303 (2013).

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  39. 39.

    Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  40. 40.

    Liang, C., Zhang, X., Yang, M. & Dong, X. Recent progress in ferroptosis inducers for cancer therapy. Adv. Mater. 31, e1904197 (2019).

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  41. 41.

    Yang, W. S. et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl Acad. Sci. USA 113, E4966–E4975 (2016).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  42. 42.

    Ursini, F. & Maiorino, M. Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic. Biol. Med. 152, 175–185 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  43. 43.

    Lu, S. C. Glutathione synthesis. Biochim Biophys. Acta 1830, 3143–3153 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  44. 44.

    Bridges, R. J., Natale, N. R. & Patel, S. A. System Xc cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br. J. Pharm. 165, 20–34 (2012).

    CAS  Article  Google Scholar 

  45. 45.

    McBean, G. J. The transsulfuration pathway: a source of cysteine for glutathione in astrocytes. Amino Acids 42, 199–205 (2012).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  46. 46.

    Yuan, H., Li, X., Zhang, X., Kang, R. & Tang, D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun. 478, 1338–1343 (2016).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  47. 47.

    Dixon, S. J. et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem. Biol. 10, 1604–1609 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Kagan, V. E. et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13, 81–90 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  49. 49.

    Feng, H. & Stockwell, B. R. Unsolved mysteries: How does lipid peroxidation cause ferroptosis? PLoS Biol. 16, e2006203 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  50. 50.

    Stoyanovsky, D. A. et al. Iron catalysis of lipid peroxidation in ferroptosis: regulated enzymatic or random free radical reaction? Free Radic. Biol. Med. 133, 153–161 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  51. 51.

    Lane, D. J. et al. Cellular iron uptake, trafficking and metabolism: key molecules and mechanisms and their roles in disease. Biochim. Biophys. Acta 1853, 1130–1144 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  52. 52.

    Coffey, R. & Ganz, T. Iron homeostasis: an anthropocentric perspective. J. Biol. Chem. 292, 12727–12734 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Kwon, M. Y., Park, E., Lee, S. J. & Chung, S. W. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget 6, 24393–24403 (2015).

    PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Gao, M. et al. Ferroptosis is an autophagic cell death process. Cell Res. 26, 1021–1032 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Hou, W. et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12, 1425–1428 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Brown, C. W. et al. Prominin2 drives ferroptosis resistance by stimulating iron export. Dev. Cell 51, 575–586 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  57. 57.

    Sun, X. et al. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene 34, 5617–5625 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Yuan, H., Li, X., Zhang, X., Kang, R. & Tang, D. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem. Biophys. Res. Commun. 478, 838–844 (2016).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  59. 59.

    Zhang, W., Gai, C., Ding, D., Wang, F. & Li, W. Targeted p53 on small-molecules-induced ferroptosis in cancers. Front Oncol. 8, 507 (2018).

    PubMed  PubMed Central  Article  Google Scholar 

  60. 60.

    Tarangelo, A. et al. p53 suppresses metabolic stress-induced ferroptosis in cancer cells. Cell Rep. 22, 569–575 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Xie, Y. et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 20, 1692–1704 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  62. 62.

    Doll, S. et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693–698 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  63. 63.

    Dodson, M., Castro-Portuguez, R. & Zhang, D. D. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 23, 101107 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. 64.

    Xu, T. et al. Molecular mechanisms of ferroptosis and its role in cancer therapy. J. Cell Mol. Med. 23, 4900–4912 (2019).

    PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Oxnard, G. R. The cellular origins of drug resistance in cancer. Nat. Med. 22, 232–234 (2016).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  66. 66.

    Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247–250 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67.

    Lorenzato, A. et al. Vitamin C restricts the emergence of acquired resistance to EGFR-targeted therapies in colorectal cancer. Cancers (Basel) 12, 685 (2020).

    CAS  Article  Google Scholar 

  68. 68.

    Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453–457 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Mao, L. et al. The emerging role of ferroptosis in non-cancer liver diseases: hype or increasing hope? Cell Death Dis. 11, 518 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Du, L., Zhang, R., Luo, T., Nie, M. & Bi, J. Effects of helium preconditioning on intestinal ischemia and reperfusion injury in rats. Shock 44, 365–370 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  71. 71.

    Mallick, I. H., Yang, W., Winslet, M. C. & Seifalian, A. M. Ischemia-reperfusion injury of the intestine and protective strategies against injury. Dig. Dis. Sci. 49, 1359–1377 (2004).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  72. 72.

    Gonzalez, L. M., Moeser, A. J. & Blikslager, A. T. Animal models of ischemia-reperfusion-induced intestinal injury: progress and promise for translational research. Am. J. Physiol. Gastrointest. Liver Physiol. 308, G63–G75 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  73. 73.

    Cheng, J. et al. The role of intestinal mucosa injury induced by intra-abdominal hypertension in the development of abdominal compartment syndrome and multiple organ dysfunction syndrome. Crit. Care 17, R283 (2013).

    PubMed  PubMed Central  Article  Google Scholar 

  74. 74.

    Berg, R. D. Bacterial translocation from the gastrointestinal tract. Trends Microbiol. 3, 149–154 (1995).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  75. 75.

    Wang, G. et al. miR-34a-5p inhibition alleviates intestinal ischemia/reperfusion-induced reactive oxygen species accumulation and apoptosis via activation of SIRT1 signaling. Antioxid. Redox Signal 24, 961–973 (2016).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  76. 76.

    Wen, S. et al. Necroptosis is a key mediator of enterocytes loss in intestinal ischaemia/reperfusion injury. J. Cell Mol. Med. 21, 432–443 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  77. 77.

    Li, Z. et al. Targeting the miR-665-3p-ATG4B-autophagy axis relieves inflammation and apoptosis in intestinal ischemia/reperfusion. Cell Death Dis. 9, 483 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  78. 78.

    Hu, Y. et al. Protective effect of dioscin against intestinal ischemia/reperfusion injury via adjusting miR-351-5p-mediated oxidative stress. Pharm. Res. 137, 56–63 (2018).

    CAS  Article  Google Scholar 

  79. 79.

    Stefanutti, G., Pierro, A., Parkinson, E. J., Smith, V. V. & Eaton, S. Moderate hypothermia as a rescue therapy against intestinal ischemia and reperfusion injury in the rat. Crit. Care Med. 36, 1564–1572 (2008).

    PubMed  Article  PubMed Central  Google Scholar 

  80. 80.

    Ozkan, O. V. et al. Resveratrol, a natural antioxidant, attenuates intestinal ischemia/reperfusion injury in rats. Tohoku J. Exp. Med. 218, 251–258 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  81. 81.

    Balogh, N. et al. Effect of deferoxamine and L-arginine treatment on lipid peroxidation in an intestinal ischaemia-reperfusion model in rats. Acta. Vet. Hung. 50, 343–356 (2002).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  82. 82.

    Li, Y. et al. Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury. Cell Death Differ. 27, 2635–2650 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  83. 83.

    Sartor, R. B. & Wu, G. D. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 152, 327–339 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  84. 84.

    Günther, C., Neumann, H., Neurath, M. F. & Becker, C. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut 62, 1062–1071 (2013).

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  85. 85.

    Werner, T. et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn’s disease-like ileitis. Gut 60, 325–333 (2011).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  86. 86.

    Carrier, J. C., Aghdassi, E., Jeejeebhoy, K. & Allard, J. P. Exacerbation of dextran sulfate sodium-induced colitis by dietary iron supplementation: role of NF-kappaB. Int. J. Colorectal Dis. 21, 381–387 (2006).

    PubMed  Article  PubMed Central  Google Scholar 

  87. 87.

    Kobayashi, Y. et al. Association between dietary iron and zinc intake and development of ulcerative colitis: a case-control study in Japan. J. Gastroenterol. Hepatol. 34, 1703–1710 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  88. 88.

    Millar, A. D., Rampton, D. S. & Blake, D. R. Effects of iron and iron chelation in vitro on mucosal oxidant activity in ulcerative colitis. Aliment Pharm. Ther. 14, 1163–1168 (2000).

    CAS  Article  Google Scholar 

  89. 89.

    Minaiyan, M., Mostaghel, E. & Mahzouni, P. Preventive therapy of experimental colitis with selected iron chelators and anti-oxidants. Int. J. Prev. Med. 3, S162–S169 (2012).

    PubMed  PubMed Central  Google Scholar 

  90. 90.

    Qi, X. et al. Mechanism and intervention measures of iron side effects on the intestine. Crit. Rev. Food Sci. Nutr. 60, 2113–2125 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  91. 91.

    Wang S., Liu W., Wang J. & Bai X. Curculigoside inhibits ferroptosis in ulcerative colitis through the induction of GPX4. Life Sci. 259, 118356 (2020).

  92. 92.

    Mayr, L. et al. Dietary lipids fuel GPX4-restricted enteritis resembling Crohn’s disease. Nat. Commun. 11, 1775 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  93. 93.

    Adedoyin, O. et al. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am. J. Physiol. Ren. Physiol. 314, F702–F714 (2018).

    CAS  Article  Google Scholar 

  94. 94.

    Zeng, L. X. et al. β-Arrestin2 encourages inflammation-induced epithelial apoptosis through ER stress/PUMA in colitis. Mucosal Immunol. 8, 683–695 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  95. 95.

    Bhardwaj, M., Leli, N. M., Koumenis, C. & Amaravadi, R. K. Regulation of autophagy by canonical and non-canonical ER stress responses. Semin Cancer Biol. 66, 116–128 (2020).

    PubMed  Article  PubMed Central  Google Scholar 

  96. 96.

    Park, E. J., Park, Y. J., Lee, S. J., Lee, K. & Yoon, C. Whole cigarette smoke condensates induce ferroptosis in human bronchial epithelial cells. Toxicol. Lett. 303, 55–66 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  97. 97.

    Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).

    Article  Google Scholar 

  98. 98.

    Benson, A. B. et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J. Natl. Compr. Canc. Netw. 16, 359–369 (2018).

    PubMed  Article  PubMed Central  Google Scholar 

  99. 99.

    Chen, P. et al. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Theranostics 10, 5107–5119 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  100. 100.

    Guo, J. et al. Ferroptosis: A novel anti-tumor action for cisplatin. Cancer Res. Treat. 50, 445–460 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  101. 101.

    Serebriiskii, I. G. et al. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nat. Commun. 10, 3722 (2019).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  102. 102.

    Xiu, C. et al. Novel benzopyran derivatives and their therapeutic applications: a patent review (2009-2016). Expert Opin. Ther. Pat. 27, 1031–1045 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  103. 103.

    Zhang, L. et al. IMCA induces ferroptosis mediated by SLC7A11 through the AMPK/mTOR pathway in colorectal cancer. Oxid. Med. Cell Longev. 2020, 1675613 (2020).

    PubMed  PubMed Central  Google Scholar 

  104. 104.

    Izumi, D. et al. Colorectal cancer stem cells acquire chemoresistance through the upregulation of F-Box/WD repeat-containing protein 7 and the consequent degradation of c-Myc. Stem Cells 35, 2027–2036 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  105. 105.

    Xu, X. et al. Targeting SLC7A11 specifically suppresses the progression of colorectal cancer stem cells via inducing ferroptosis. Eur. J. Pharm. Sci. 152, 105450 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  106. 106.

    Park, S., Oh, J., Kim, M. & Jin, E. J. Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis. Anim. Cells Syst. (Seoul.) 22, 334–340 (2018).

    CAS  Article  Google Scholar 

  107. 107.

    Angius, A. et al. Integrated analysis of miRNA and mRNA endorses a twenty mirnas signature for colorectal carcinoma. Int. J. Mol. Sci. 20, 4067 (2019).

    CAS  PubMed Central  Article  Google Scholar 

  108. 108.

    Hong, S. H. et al. Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent PUMA expression. Oncotarget 8, 115164–115178 (2017).

    PubMed  PubMed Central  Article  Google Scholar 

  109. 109.

    Lee, Y. S. et al. Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5. J. Cell Biochem. 120, 928–939 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  110. 110.

    Hasan, M., Reddy, S. M. & Das, N. K. Ferritinophagy is not required for colon cancer cell growth. Cell Biol. Int. 44, 2307–2314 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  111. 111.

    Li, Y. et al. H(2) S-scavenged and activated iron oxide-hydroxide nanospindles for MRI-guided photothermal therapy and ferroptosis in colon cancer. Small 16, e2001356 (2020).

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  112. 112.

    Lu, D. et al. ACADSB regulates ferroptosis and affects the migration, invasion and proliferation of colorectal cancer cells. Cell Biol. Int. 44, 2334–2343 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  113. 113.

    Ousingsawat, J., Schreiber, R. & Kunzelmann, K. TMEM16F/Anoctamin 6 in ferroptotic cell death. Cancers (Basel) 11, 625 (2019).

    CAS  PubMed Central  Article  Google Scholar 

Download references


We would like to thank Editage ( for English language editing.


This work was supported by grants from the National Natural Science Foundation of China (#81630018, #82070538, #81870374), Guangzhou Science and Technology Department (#202002030041), Guangdong Science and Technology Department (#2017A030306021), and the Fundamental Research Funds for the Central Universities (#19ykzd11).

Author information




Guarantor of the article: S.Z. S.Z. and M.C. designed and oversaw the study. S.X. and Y.H. wrote and revised the manuscript. S.Z., M.C., P.C., and L.L. revised the contents of the manuscript. All authors approved the final manuscript.

Corresponding authors

Correspondence to Minhu Chen or Shenghong Zhang.

Ethics declarations


This paper has been approved by the Medical Ethics Committee of the First Affiliated Hospital, Sun Yat-sen University.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Edited by F. Pentimalli

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xu, S., He, Y., Lin, L. et al. The emerging role of ferroptosis in intestinal disease. Cell Death Dis 12, 289 (2021).

Download citation

Further reading


Quick links